Myeloma 2015 | Immunotherapy for the treatment of multiple myeloma

David Avigan

At the Myeloma 2015, Dr David Avigan (Beth Israel Deaconess Medical Center, Boston, MA) discusses the development of immune checkpoint inhibitors, including anti-PD-1 antibodies, for the treatment of multiple myeloma (MM). An emerging focus has been on combination therapies and enhancing the anti-MM immune response during treatment using vaccination approaches.

Share this video